secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001493152-24-035625
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mira Pharma selects neuropathic pain for Ketamir-2, submits pre-IND request to FDA
--------------------------------------------------------------------------------

- Selected neuropathic pain as primary indication for oral ketamine analog Ketamir-2.
- Submitted pre-IND meeting request to FDA; meeting expected October 2024.
- Plans to begin human trials in Q1 2025 following IND submission.
- No financial details or trial data disclosed in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224035625/0001493152-24-035625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224035625/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-035625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer